Full Content is available to subscribers

Subscribe/Learn More  >
Proceedings Article

Imaging enabled platforms for development of therapeutics

[+] Author Affiliations
Jonathan Celli, Conor L. Evans, Adnan O. Abu-Yousif, Bryan Q. Spring, Tayyaba Hasan

Wellman Ctr. for Photomedicine, Massachusetts General Hospital, Harvard School of Medicine (USA)

Imran Rizvi

Wellman Ctr. for Photomedicine, Massachusetts General Hospital, Harvard School of Medicine (USA) and Dartmouth College (USA)

Adam R. Blanden

Wellman Ctr. for Photomedicine, Massachusetts General Hospital, Harvard School of Medicine (USA) and State Univ. of New York (USA)

Alona Muzikansky, Dianne M. Finkelstein

Biostatistics Ctr., Massachusetts General Hospital (USA)

Brian W. Pogue

Dartmouth College (USA)

Proc. SPIE 7910, Reporters, Markers, Dyes, Nanoparticles, and Molecular Probes for Biomedical Applications III, 791002 (February 15, 2011); doi:10.1117/12.877293
Text Size: A A A
From Conference Volume 7910

  • Reporters, Markers, Dyes, Nanoparticles, and Molecular Probes for Biomedical Applications III
  • Samuel Achilefu; Ramesh Raghavachari
  • San Francisco, California, USA | January 22, 2011

abstract

Advances in imaging and spectroscopic technologies have enabled the optimization of many therapeutic modalities in cancer and noncancer pathologies either by earlier disease detection or by allowing therapy monitoring. Amongst the therapeutic options benefiting from developments in imaging technologies, photodynamic therapy (PDT) is exceptional. PDT is a photochemistry-based therapeutic approach where a light-sensitive molecule (photosensitizer) is activated with light of appropriate energy (wavelength) to produce reactive molecular species such as free radicals and singlet oxygen. These molecular entities then react with biological targets such as DNA, membranes and other cellular components to impair their function and lead to eventual cell and tissue death. Development of PDT-based imaging also provides a platform for rapid screening of new therapeutics in novel in vitro models prior to expensive and labor-intensive animal studies. In this study we demonstrate how an imaging platform can be used for strategizing a novel combination treatment strategy for multifocal ovarian cancer. Using an in vitro 3D model for micrometastatic ovarian cancer in conjunction with quantitative imaging we examine dose and scheduling strategies for PDT in combination with carboplatin, a chemotherapeutic agent presently in clinical use for management of this deadly form of cancer.

© (2011) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Citation

Jonathan Celli ; Imran Rizvi ; Adam R. Blanden ; Conor L. Evans ; Adnan O. Abu-Yousif, et al.
"Imaging enabled platforms for development of therapeutics", Proc. SPIE 7910, Reporters, Markers, Dyes, Nanoparticles, and Molecular Probes for Biomedical Applications III, 791002 (February 15, 2011); doi:10.1117/12.877293; http://dx.doi.org/10.1117/12.877293


Access This Proceeding
Sign in or Create a personal account to Buy this proceeding ($15 for members, $18 for non-members).

Figures

Tables

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Advertisement


 

  • Don't have an account?
  • Subscribe to the SPIE Digital Library
  • Create a FREE account to sign up for Digital Library content alerts and gain access to institutional subscriptions remotely.
Access This Proceeding
Sign in or Create a personal account to Buy this proceeding ($15 for members, $18 for non-members).
Access This Proceeding
Sign in or Create a personal account to Buy this article ($15 for members, $18 for non-members).
Access This Chapter

Access to SPIE eBooks is limited to subscribing institutions and is not available as part of a personal subscription. Print or electronic versions of individual SPIE books may be purchased via SPIE.org.